About Alector
Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, while also attracting funding and partnerships through their research findings.
San Francisco, CaliforniaHeadquarters
2013Year Founded
$189.2MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Flexible Work Hours
Hybrid Work Options
Risks
Failure in AL002 trial may decrease investor confidence and financial stability.
Reliance on external financing increases financial risk if therapies don't succeed commercially.
Increased competition in neurodegenerative market could impact Alector's market share.
Differentiation
Alector combines antibody technology with neuroimmunology for novel neurodegenerative therapies.
Strategic alliance with Adimab enhances Alector's antibody discovery and optimization capabilities.
Focus on genetically validated therapies aligns with personalized medicine trends.
Upsides
Increased interest in neuroimmunology boosts investment and collaboration opportunities for Alector.
AI-driven drug discovery enhances efficiency, aligning with Alector's technology-driven strategy.
Expansion of strategic alliances offers collaboration and resource sharing opportunities for Alector.
Funding
Total raised$189.20 M
Latest valuation$1.30 B
StageIPO
POST IPO DEBT
10/31/2024$50
POST IPO EQUITY
12/31/2023$75
IPO
1/31/2019$176
$1.30 BSERIES D
12/31/2015$30
$147.50 MSERIES C
8/31/2015$32
$160.00 M